MARKET

AUTL

AUTL

AUTOLUS THERAPEUTICS PLC
NASDAQ
1.570
+0.090
+6.08%
Closed 19:47 12/04 EST
OPEN
1.490
PREV CLOSE
1.480
HIGH
1.610
LOW
1.460
VOLUME
3.78M
TURNOVER
0
52 WEEK HIGH
3.450
52 WEEK LOW
1.105
MARKET CAP
417.84M
P/E (TTM)
-1.8589
1D
5D
1M
3M
1Y
5Y
1D
Autolus Therapeutics Appoints Ryan Richardson to Board
TipRanks · 2d ago
Weekly Report: what happened at AUTL last week (1124-1128)?
Weekly Report · 4d ago
Why Is Autolus Therapeutics Stock Trading Higher On Tuesday?
Benzinga · 11/25 17:37
Midday Fly By: Alphabet continues ascent, fueled by AI optimism
TipRanks · 11/25 17:06
Abercrombie & Fitch, Titan Machinery, Zoom Communications, Woodward And Other Big Stocks Moving Higher On Tuesday
Benzinga · 11/25 15:03
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 11/25 12:05
Autolus Therapeutics announces NICE draft guidance recommending Aucatzyl
TipRanks · 11/25 10:10
Autolus Wins UK Backing for New CAR-T Cancer Therapy AUCATZYL for Adults With Aggressive Leukemia
Benzinga · 11/25 09:07
More
About AUTL
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.

Webull offers Autolus Therapeutics PLC (ADR) stock information, including NASDAQ: AUTL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AUTL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AUTL stock methods without spending real money on the virtual paper trading platform.